Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry.
CFTR gene
CFTR modulators
Cystic fibrosis
Next-generation sequencing
Patient registry
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 10 2021
02 10 2021
Historique:
received:
06
04
2021
accepted:
19
09
2021
entrez:
3
10
2021
pubmed:
4
10
2021
medline:
7
10
2021
Statut:
epublish
Résumé
Specialized clinical care for cystic fibrosis (CF) in Cyprus, a small island country, has been implemented since the 1990s. However, only recently, a national CF patient registry has been established for the systematic recording of patients' data. In this study, we aim to present data on the epidemiological, genotypic and phenotypic features of CF patients in the country from the most recent data collection in 2019, with particular emphasis on notable rare or unique cases. Overall, data from 52 patients are presented, 5 of whom have deceased and 13 have been lost to follow-up in previous years. The mean age at diagnosis was 7.2 ± 12.3 years, and the mean age of 34 alive patients by the end of 2019 was 22.6 ± 13.2 years. Patients most commonly presented at diagnosis with acute or persistent respiratory symptoms (46.2%), failure to thrive or malnutrition (40.4%), and dehydration or electrolyte imbalance (32.7%). Sweat chloride levels were diagnostic (above 60 mmol/L) in 81.8% of examined patients. The most common identified mutation was p.Phe508del (F508del) (45.2%), followed by p.Leu346Pro (L346P) (6.7%), a mutation detected solely in individuals of Cypriot descent. The mean BMI and FEV CF patient registries are particularly important in small or isolated populations, such as in Cyprus, with rare or unique disease cases. Their operation is necessary for the optimization of clinical care provided to CF patients, enabling their majority to benefit from evolving advances in precision medicine.
Sections du résumé
BACKGROUND
Specialized clinical care for cystic fibrosis (CF) in Cyprus, a small island country, has been implemented since the 1990s. However, only recently, a national CF patient registry has been established for the systematic recording of patients' data. In this study, we aim to present data on the epidemiological, genotypic and phenotypic features of CF patients in the country from the most recent data collection in 2019, with particular emphasis on notable rare or unique cases.
RESULTS
Overall, data from 52 patients are presented, 5 of whom have deceased and 13 have been lost to follow-up in previous years. The mean age at diagnosis was 7.2 ± 12.3 years, and the mean age of 34 alive patients by the end of 2019 was 22.6 ± 13.2 years. Patients most commonly presented at diagnosis with acute or persistent respiratory symptoms (46.2%), failure to thrive or malnutrition (40.4%), and dehydration or electrolyte imbalance (32.7%). Sweat chloride levels were diagnostic (above 60 mmol/L) in 81.8% of examined patients. The most common identified mutation was p.Phe508del (F508del) (45.2%), followed by p.Leu346Pro (L346P) (6.7%), a mutation detected solely in individuals of Cypriot descent. The mean BMI and FEV
CONCLUSIONS
CF patient registries are particularly important in small or isolated populations, such as in Cyprus, with rare or unique disease cases. Their operation is necessary for the optimization of clinical care provided to CF patients, enabling their majority to benefit from evolving advances in precision medicine.
Identifiants
pubmed: 34600583
doi: 10.1186/s13023-021-02049-z
pii: 10.1186/s13023-021-02049-z
pmc: PMC8487500
doi:
Substances chimiques
CFTR protein, human
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
409Informations de copyright
© 2021. The Author(s).
Références
Hum Genet. 2001 Dec;109(6):592-601
pubmed: 11810271
Am J Hum Genet. 1992 Jan;50(1):222-8
pubmed: 1370365
J Cyst Fibros. 2015 Sep;14(5):561-70
pubmed: 26115565
Eur J Hum Genet. 1997 May-Jun;5(3):149-55
pubmed: 9272738
Pediatr Pulmonol. 2020 Feb;55(2):541-548
pubmed: 31710166
N Engl J Med. 2011 Nov 3;365(18):1663-72
pubmed: 22047557
J Hum Genet. 2010 Jan;55(1):23-6
pubmed: 19893581
J Cyst Fibros. 2018 May;17(3):297-305
pubmed: 29275954
Pediatr Pulmonol. 2017 Nov;52(S48):S44-S51
pubmed: 28910520
BMC Pulm Med. 2014 May 26;14:89
pubmed: 24886346
J Cyst Fibros. 2018 Jul;17(4):433-440
pubmed: 29555479
Saudi J Kidney Dis Transpl. 2013 Mar;24(2):292-6
pubmed: 23538352
Clin Genet. 2003 May;63(5):400-9
pubmed: 12752573
Ann Biol Clin (Paris). 2005 Nov-Dec;63(6):627-30
pubmed: 16330381
J Cyst Fibros. 2008 Sep;7(5):347-51
pubmed: 18280224
J Cyst Fibros. 2010 Dec;9(6):406-10
pubmed: 20797923
Curr Opin Pulm Med. 2003 Nov;9(6):498-503
pubmed: 14534402
JAMA. 2000 Oct 11;284(14):1814-9
pubmed: 11025834
Ann Hum Genet. 2010 Sep 1;74(5):463-9
pubmed: 20560922
Mol Cell Probes. 1996 Aug;10(4):315-8
pubmed: 8865181
N Engl J Med. 2018 Oct 25;379(17):1612-1620
pubmed: 30334692
N Engl J Med. 2015 Jul 16;373(3):220-31
pubmed: 25981758
J Cyst Fibros. 2021 Jan;20(1):68-77
pubmed: 32967799
BMC Med Genet. 2020 May 1;21(1):89
pubmed: 32357917
Hum Mutat. 2002 Jun;19(6):575-606
pubmed: 12007216
J Cyst Fibros. 2008 Jan;7(1):54-9
pubmed: 17572159
J Pediatr. 1998 Apr;132(4):589-95
pubmed: 9580754
BMJ Qual Saf. 2014 Apr;23 Suppl 1:i9-14
pubmed: 24443584
J Cyst Fibros. 2004 Dec;3(4):265-72
pubmed: 15698946
Case Rep Genet. 2014;2014:613863
pubmed: 24649380
Ann Trop Paediatr. 1995 Dec;15(4):269-72
pubmed: 8687200
Gene. 2012 Jun 1;500(2):194-8
pubmed: 22484595
Hum Genet. 1994 May;93(5):529-32
pubmed: 7513296
J Cyst Fibros. 2018 Mar;17(2):153-178
pubmed: 29506920
Eur J Hum Genet. 2009 Apr;17(4):537-40
pubmed: 19050730
Clin Genet. 2007 Mar;71(3):290-2
pubmed: 17309655
Springerplus. 2016 May 20;5(1):686
pubmed: 27347467
Ann Trop Paediatr. 2005 Jun;25(2):119-24
pubmed: 15949200
Pediatrics. 1959 Mar;23(3):545-9
pubmed: 13633369
J Pediatr. 2017 Feb;181S:S4-S15.e1
pubmed: 28129811
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 32732328
N Engl J Med. 2019 Nov 7;381(19):1809-1819
pubmed: 31697873
J Cyst Fibros. 2011 Jun;10 Suppl 2:S86-102
pubmed: 21658649
Curr Protoc Hum Genet. 2019 Sep;103(1):e93
pubmed: 31479589